Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28274542 | 0.93 | HTR1B (0.42) | HTR1BHTR1DSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL28274536 | 0.93 | HTR1B (0.42) | HTR1BHTR1DSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL30301305 | 0.82 | HTR1B (0.50) | HTR1BHTR1DSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL29862254 | 0.82 | HTR1B (0.50) | HTR1BHTR1DSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL1509321 | 0.82 | HTR1B (0.50) | HTR1BHTR1DSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL4253392 | 0.82 | SIGMAR1 (0.51) | SIGMAR1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL9312711 | 0.81 | HTR1B (0.49) | HTR1BHTR1DSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL1593235 | 0.80 | SIGMAR1 (0.43) | HTR1BSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL6568722 | 0.79 | SIGMAR1 (0.50) | HTR1BHTR1DSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL5074484 | 0.79 | ALDH1A1 (0.44) | HTR1BHTR1DALDH1A1KMT2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-03-29 | — | — | US | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-11-03 | — | — | US | disclosed |
| US-9458082-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9422225-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2998288-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-1954669-B1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20140296339-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2014-10-02 | — | — | US | disclosed |
| EP-1680409-A2 | PH SENSITIVE PRODRUGS OF 2,6-DIISOPROPYLPHENOL | Auspex Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006041921-A2 | PREPARATION AND USES OF RHODANINE DERIVATIVES | AUSPEX PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014800-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050234050-A1 | Ph sensitive prodrugs of 2,6-diisopropylphenol | AUSPEX PHARMACEUTICALS INC | 2005-10-20 | — | — | US | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005044201-A2 | PH SENSITIVE PRODRUGS OF 2,6-DIISOPROPYLPHENOL | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005011573-A2 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234050-A1 | Ph sensitive prodrugs of 2,6-diisopropylphenol | CYP2D6, CYP2B6, CYP2A6 | HTR1B 1368/4885HTR1D 2471/4885SIGMAR1 87/4885 |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | HTR1B 16/4885HTR1D 52/4885SIGMAR1 186/4885 |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | HTR1B 16/4885HTR1D 52/4885SIGMAR1 186/4885 |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | HTR1B 16/4885HTR1D 52/4885SIGMAR1 186/4885 |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | HTR1B 16/4885HTR1D 52/4885SIGMAR1 186/4885 |
| US-20060014800-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | IGF1R, INSR, MC1R | HTR1B 3764/4885HTR1D 3681/4885SIGMAR1 4334/4885 |
| US-20140296339-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | HTR1B 16/4885HTR1D 52/4885SIGMAR1 186/4885 |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | HTR1B 16/4885HTR1D 52/4885SIGMAR1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.